Newborn and Infant Nursing Reviews
Volume 9, Issue 1 , Pages 18-30 , March 2009

Progress in Congenital Cardiac Care for Newborns and Infants: The Emerging Role of “Off-label” Medications

  • Marilyn Torres, Pharm D

      Affiliations

    • Cardiovascular Intensive Care Program, Miami Children's Hospital, Miami, FL
    • Corresponding Author InformationAddress correspondence to Marilyn Torres, Pharmacy Department, Miami Children's Hospital, 3100 SW 62nd Avenue, Miami, FL 33155.
    • ,
  • Jo Ann Nieves, MSN, CPN, ARNP, PNP-BC

      Affiliations

    • Pediatric Cardiology, Miami Children's Hospital, Miami, FL

References 

  1. Pierpont MA, Basson CT, Benson DW, et al. Genetic basis for congenital heart defects: current knowledge. A scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: Endorsed by the American Academy of Pediatrics. Circulation. 2007;115:3015–3038
  2. Botto LD, Goldmuntz E. Epidemiology and prevention of congenital heart disease. In:  Allen HD,  Driscoll DJ,  Feltes TF,  Shaddy RE editor. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed.. Philadelphia: Lippincott Williams & Wilkins; 2008;p. 524–544
  3. Society of thoracic surgeons executive summary. Congenital heart surgery database. http://www.sts.org/sections/stsnationaldatabase/publications/executive/article.html[accessed 10/30/2008]
  4. Wernovsky G, Chang AC, Wessel DL, Ravishankar C. Cardiac intensive care. In:  Allen HD,  Driscoll DJ,  Feltes TF,  Shaddy RE editor. Moss and Adams' heart disease in infants, children, and adolescent including the fetus and young adult. 7th ed.. Philadelphia: Lippincott Williams & Wilkins; 2008;p. 448–480
  5. Costello JM, Almodovar MC. Emergency card for infants and children with acute cardiac disease. Clin Pediatr Emerg Med. 2007;8:[MD Consult]
  6. Galantowicz M, Cheatham JP, Phillips A, et al. Hybrid approach for hypoplastic left heart syndrome: intermediate results after the learning curve. Ann Thorac Surg. 2008;85:2063–2070
  7. Daniels CJ. The adolescent and adult a with congenital heart disease. In:  Allen HD,  Driscoll DJ,  Feltes TF,  Shaddy RE editor. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed.. Philadelphia: Lippincott Williams & Wilkins; 2008;p. 1370–1396
  8. Shah SS, Hall M, Goodman DM, et al. Off label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–290
  9. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107:996–1002
  10. Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants: a comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation. 1995;92:2226–2235
  11. Tourneux P, Thameur R, Abdel Gérard K, Laurent S. Noradrenaline for management of septic shock refractory to fluid and dopamine or dobutamine in full-term newborn infants. Acta Paediatr. 2008;1–4
  12. Ward RM, Lugo RA. Cardiovascular drugs for the newborn. Clin Perinatol. 2005;32:979–997
  13. Strodtbeck F, Theorll C. Drug therapy for infants with cardiac disease. Newborn Infant Nurs Rev. 2002;60:60–73
  14. May LE. Pediatric heart surgery: a ready reference for professionals. 4th ed.. Milwaukee (Wis): maxiSHARE; 2008;
  15. In:  Allen HD,  Driscoll DJ,  Feltes TF,  Shaddy RE editor. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed.. Philadelphia: Lippincott Williams & Wilkins; 2008;
  16. Chang AC, Atz AM, Andrew M, Wernovsky G, Redmond B, Wessel D. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med. 1995;23:1907–1914
  17. Barton P, Garcia J, Kouatli A, et al. Hemodynamic effects of IV milrinone lactate in pediatric patients with septic shock: a prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest. 1996;109:1302–1312
  18. Henderson L, Tenero D, Baidoo C, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol. 2006;98(Suppl):17L–26L
  19. Moser M, Frishman W. Results of therapy with carvedilol, a betablocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens. 1998;11:15–22
  20. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003;63:1697–1741
  21. Bristow M, Roden R, Lowes B, Gilbert E, Eichhorn E. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol. 1998;21(Suppl):1–3
  22. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621
  23. Bruns L, Canter C. Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?. Paediatr Drugs. 2002;4:771–778
  24. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171–1179
  25. Buck M. Use of carvedilol in children with cardiac failure. Pediatr Pharm. 2005;
  26. Costello J. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Pediatr Crit Care Med. 2006;7:28–33
  27. Moffett B, Orellana R. Renal effects of fenoldopam in critically ill pediatric patients. Pediatr Crit Care Med. 2008;9:403–406
  28. Gomez HJ, Cirillo VJ, Jones KH. The clinical pharmacology of enalapril. J Hypertens Suppl. 1983;1:65–70
  29. Hardman JG, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition.
  30. Sweet CS, Gaul SL, Reitz PM, Blaine EH, Ribeiro LT. Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure. J Hypertens Suppl. 1983;1:53–63
  31. Calabro R, Pisacane C, Pacileo G, Russo M. Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. Am Heart J. 1999;138:955–961
  32. Seguchi M, Nakazawa M, Momma K. Effect of enalapril on infants and children with congestive heart failure. Cardiol Young. 1992;2:14–19
  33. Hoffman TM, Welty SE. Physiology of the preterm and term infant. In:  Allen HD,  Driscoll DJ,  Feltes TF,  Shaddy RE editor. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult. 7th ed.. Philadelphia: Lippincott Williams & Wilkins; 2008;p. 440–447
  34. Wessel DL, Laussen PC. Intensive care unit. In:  Keane JF,  Lock JE,  Fyler DC editor. Nadas' pediatric cardiology. 2nd ed.. Philadelphia: Elsevier; 2006;
  35. Nieves J. Pulmonary hypertension: nursing plan of care. In:  Verger JT,  Lebet LM editor. American Association of Critical Care Nurses procedural manual for pediatric acute and critical care. St. Louis: Saunders, Elsevier; 2008;p. 523–529
  36. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med. 2007;35:2037–2050
  37. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–1436
  38. Fineman JR, Heymann MA, Morin FC. Fetal and postnatal circulations: pulmonary and persistent pulmonary hypertension of the newborn. In:  Allen HD,  Clark EB,  Gutgesell HP,  Driscoll DJ editor. Moss & Adams heart disease in infants, children, and adolescents including the fetus and young adult. 6th ed.. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 41–52
  39. Gamillscheg A, Zobel G, Urlesberger B, et al. Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anastomosis. J Thorac Cardiovasc Surg. 1997;113:435–442
  40. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celemajer DS. Inhaled nitric oxide and prevention pulmonary hypertension after congenital heart surgery: a randomized double-blind study. Lancet. 2000;356:1464–1469
  41. Roberts JD, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation. 1993;87:447–453
  42. Miller OI, Celermajer DS, Deanfield JE, Macrae DJ. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg. 1994;108:487–494
  43. Khazin V, Kaufman Y, Zabeeda D, et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth. 2004;18:156–159
  44. Knight D. Newborn drug services: nitric oxide. http://www.akhealth.co.nz/newborn/DrugProtocols/NitricOxidePharmacology.htm2008;
  45. Atz AM. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg. 1996;62:1759–1764
  46. Schulze-Neick I, Werner H, Penny DJ, Alexi-Meskishvili V, Lange PE. Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension. Intensive Care Med. 1999;25:76–80
  47. Poongundran M, Theilen U, Warwick W, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006;174:1042–1047
  48. Atz AM, Lefler AK, Fairbrother DL, et al. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg. 2002;124:628–629
  49. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91:307–310
  50. Raja SG, Danton MD, MacArthur KJ, Pollock JC. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects. J Cardiothorac Vasc Anesth. 2007;21:203–207
  51. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multi-center, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54
  52. Tracleer. web site http://www.rxlist.com/tracleer-drug.htm2008;
  53. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years with pulmonary arterial hypertension: results from the European post-marketing surveillance program. Pediatr Res. 2008;64:200–204
  54. Krishnan U, Krishnan S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol. 2008;[Electronic publication]
  55. Goissen C, Ghyselen L, Tourneux P, Krim G, et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur J Pediatr. 2008;167:437–440
  56. Dunbar D, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol. 2004;93:http://www.mdconsult.com/das/article/body/110782929-2/jorg=journal&source=&sp=14582946&sid=0/N/409659/1.html?issn=00029149
  57. Meyers JL. Pulmonary hypertension, Eisenmenger syndrome. http://www.emedicine.com/ped/TOPIC2528.htm2007;
  58. Iloprost (Ventavis®) package insert.
  59. Ivy D. Studies of inhaled iloprost in children with pulmonary hypertension. In: CHEST 2006: 72nd Annual International Scientific Assembly of the American College of Chest Physicians. October 21-26. 2006;
  60. Tweddell JS. Aspirin: a treatment for the headache of shunt-dependent pulmonary blood flow and parallel circulation?. Circulation. 2007;116:236–237
  61. Li JS, Yow E, Berezny KY, et al. Clinical outcomes of palliative surreys including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease—does aspirin make a difference?. Circulation. 2007;116:293–297
  62. Vitiello R, McCrindle BW, Nykanen D, Freedom RM, Benson LN. Complications associated with pediatrics cardiac catheterization. J Am Coll Cardiol. 1998;32:1433–1440
  63. Segel GB, Francis CW. Anticoagulant proteins in childhood venous and arterial thrombosis: a review. Blood Cell Mol Dis. 2000;26:540–560
  64. Fenton KN, Keiwers RD, Rebovich B, Pigula FA. Interim mortality in infants with systemic to pulmonary artery shunts. Ann Thorac Surg. 2003;76:152–157
  65. Motz W, Wessel A, Ruschewski W, Bürsch J. Reduced frequency of occlusion of aorto-pulmonary shunts in infants receiving aspirin. Cardiol Young. 1999;9:474–477
  66. Li JS, Yow E, Berenzy KY, et al. Doping of clopidogrel for platelet inhibition in infants and children. Primary results of the platelet inhibition in children on clopidogrel (PICOLO) trial. Circulation. 2008;117:553–559
  67. Maltz LA, Gauvreau K, Connor JA, Jenkins KJ. Clopidogel in a pediatric population: prescribing practice and outcomes from a single center. Pediatr Cardiol. 2008;[Electronic publication]
  68. Berkenbosch J, Wankum P, Tobias J. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children. Pediatr Crit Care Med. 2005;6:
  69. Buck M, Wilson D. Use of Dexmedetomidine in the pediatric intensive care unit. Pharmacotherapy. 2008;28:51–57
  70. Gillis JC, Brogden RN. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188
  71. Hardman JG, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Ketorolac tromethamine injection [package insert]. North Chicago (Ill): Abbott Laboratories, Inc.; 1997;
  72. Buck ML. Clinical experience with ketorolac in children. Ann Pharmacother. 1994;28:1009–1013
  73. Moffett BS, Wann TI, Carberry KE, Mott AR. Safety of ketorolac in neonates and infants after cardiac surgery. Paediatr Anaesth. 2006;16:424–428
  74. Torres M, et al. Tenth annual update on pediatric cardiovascular disease. Continuous local anesthetic infusion improves pain control in children after median sternotomy [Research abstract].
  75. Rusconi P, Gómez-Marín O, Rossique-González M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. The Journal of Heart and Lung Transplantation 23:832-838.

PII: S1527-3369(08)00168-2

doi: 10.1053/j.nainr.2008.12.006

Newborn and Infant Nursing Reviews
Volume 9, Issue 1 , Pages 18-30 , March 2009

Article Tools

* Image Usage & Resolution